Notably, FXR and TGR5 agonists have been shown to reverse diet-induced hepatic steatosis, inflammation, and fibrosis, an effect mediated through up-regulation of mitochondrial function within hepatocytes [24]. This evidence concerns the gene NR1H4 and fatty liver disease.